BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) infections with a plasma efavirenz concentration of <1,000 ng/mL appear to have a high risk for the emergence of drug resistance. In the present study, we assessed the influence of the CYP2B6 polymorphism on the plasma efavirenz level. METHODS: CYP2B6 T18492C (rs2279345) in 149 HIV-infected Thai adults were genotyped. Plasma efavirenz concentrations 12 h after dosing were measured using a validated high-performance liquid chromatography. The relationship between the plasma efavirenz level and the CYP2B6 T18492C polymorphism were analysed. RESULTS: Among the 149 patients, the frequency of T18492C heterozygous (T/C) and homozygous mutant (C/C) was 38.26 % (n = 57) and 6.04 % (n = 9), respectively. In the entire cohort, the median efavirenz plasma concentration was 2,410 ng/mL [interquartile range (IQR) 1,460-4,120 ng/mL]. The plasma efavirenz concentration for patients with 18492CC (1,200 ng/mL, IQR 1,050-1,990 ng/mL) or 18492TC (1,900 ng/mL, IQR 1,320-2,510 ng/mL) genotypes were significantly lower than those with homozygous wild type (3,380 ng/mL, IQR 2,040-5,660 ng/mL), P-value < 0.001. CONCLUSIONS: The CYP2B6 T18492C polymorphism was significantly associated with lower efavirenz concentrations compared to those with homozygous wild type in HIV-1 infections. The genetic polymorphism CYP2B6 T18492C may be useful for the optimised efavirenz dose. Further studies in the clinical setting will need to be conducted before such an approach can be recommended for widespread use.
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) infections with a plasma efavirenz concentration of <1,000 ng/mL appear to have a high risk for the emergence of drug resistance. In the present study, we assessed the influence of the CYP2B6 polymorphism on the plasma efavirenz level. METHODS:CYP2B6 T18492C (rs2279345) in 149 HIV-infected Thai adults were genotyped. Plasma efavirenz concentrations 12 h after dosing were measured using a validated high-performance liquid chromatography. The relationship between the plasma efavirenz level and the CYP2B6 T18492C polymorphism were analysed. RESULTS: Among the 149 patients, the frequency of T18492C heterozygous (T/C) and homozygous mutant (C/C) was 38.26 % (n = 57) and 6.04 % (n = 9), respectively. In the entire cohort, the median efavirenz plasma concentration was 2,410 ng/mL [interquartile range (IQR) 1,460-4,120 ng/mL]. The plasma efavirenz concentration for patients with 18492CC (1,200 ng/mL, IQR 1,050-1,990 ng/mL) or 18492TC (1,900 ng/mL, IQR 1,320-2,510 ng/mL) genotypes were significantly lower than those with homozygous wild type (3,380 ng/mL, IQR 2,040-5,660 ng/mL), P-value < 0.001. CONCLUSIONS: The CYP2B6 T18492C polymorphism was significantly associated with lower efavirenz concentrations compared to those with homozygous wild type in HIV-1 infections. The genetic polymorphism CYP2B6 T18492C may be useful for the optimised efavirenz dose. Further studies in the clinical setting will need to be conducted before such an approach can be recommended for widespread use.
Authors: Joep J van Oosterhout; Neena Bodasing; Johnstone J Kumwenda; Cooper Nyirenda; Jane Mallewa; Paul R Cleary; Michel P de Baar; Rob Schuurman; David M Burger; Eduard E Zijlstra Journal: Trop Med Int Health Date: 2005-05 Impact factor: 2.622
Authors: M Fabbiani; L Bracciale; E Ragazzoni; R Santangelo; P Cattani; S Di Giambenedetto; G Fadda; P Navarra; R Cauda; A De Luca Journal: Infection Date: 2011-08-25 Impact factor: 3.553
Authors: C Sukasem; V Churdboonchart; S Chasombat; S Kohreanudom; C Watitpun; E Pasomsub; W Piroj; M Tiensuwan; W Chantratita Journal: Infection Date: 2007-04 Impact factor: 3.553
Authors: Marc Pfister; Line Labbé; Scott M Hammer; John Mellors; Kara K Bennett; Susan Rosenkranz; Lewis B Sheiner Journal: Antimicrob Agents Chemother Date: 2003-01 Impact factor: 5.191
Authors: Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas Journal: Clin Pharmacol Ther Date: 2019-07-05 Impact factor: 6.875
Authors: Marijana Vujkovic; Scarlett L Bellamy; Athena F Zuppa; Marc R Gastonguay; Ganesh S Moorthy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Brian L Strom; Gregory P Bisson; Richard Aplenc; Robert Gross Journal: Pharmacogenomics J Date: 2018-06-01 Impact factor: 3.550
Authors: Johanna Penell; Lars Lind; Tove Fall; Anne-Christine Syvänen; Tomas Axelsson; Per Lundmark; Andrew P Morris; Cecilia Lindgren; Anubha Mahajan; Samira Salihovic; Bert van Bavel; Erik Ingelsson; P Monica Lind Journal: Environ Health Date: 2014-05-08 Impact factor: 5.984
Authors: Sandra Soeria-Atmadja; Emma Österberg; Lars L Gustafsson; Marja-Liisa Dahl; Jaran Eriksen; Johanna Rubin; Lars Navér Journal: PLoS One Date: 2017-09-08 Impact factor: 3.240